Biotechnology News and Research

RSS

Complete Genomics, SAIC-Frederick collaborate to validate somatic mutations from pediatric cancer cases

Complete Genomics Inc., a life sciences company focused on human genome sequencing, today announced a collaboration to identify and validate somatic mutations from 50 pediatric cancer cases from multiple research centers across the United States.

7 Sep 2010

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced today that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery. There currently are no approved drugs for preventing post-surgical scarring in glaucoma, and there are no approved anti-fibrotic drug therapies in the U.S. or Europe for any fibrotic disease.

7 Sep 2010

Bend Research expands hot-melt extrusion pharmaceutical manufacturing capabilities

Bend Research Inc., a leading independent drug-formulation development and manufacturing company, announced today that it is expanding its pharmaceutical manufacturing capabilities for hot-melt extrusion.

7 Sep 2010

Researchers reveal new details on bacterial cannibalism

Researchers at the University of California, San Diego have revealed new details about how cannibalistic bacteria identify peers suitable for consumption. The work, which employed imaging mass spectrometry, is a first step toward a broader effort to map all signaling molecules between organisms.

4 Sep 2010

Exelixis grants 25,200 shares to nine new employees

Exelixis, Inc. announced that today it granted restricted stock units representing an aggregate of 25,200 shares of Exelixis common stock to nine new employees.

4 Sep 2010

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

As the summer comes to a close, I wanted to update you on the Company's accomplishments this year, which set the stage for an exciting fall. The first eight months of the year have been very successful, with the Company attaining many of its goals, despite a very difficult economic environment, which has created challenges for many small biotechnology companies. Today, IMUC is in its best financial position ever and well positioned to validate the success it achieved in a Phase I trial for ICT-107, its dendritic cell-based cancer vaccine product candidate.

3 Sep 2010

Omnicare, Walgreen announce closing of transaction

Omnicare, Inc. and Walgreen Co. today announced a transaction in which Omnicare will acquire substantially all of the assets of Walgreens long-term care pharmacy business. In exchange, Walgreens will acquire substantially all of the assets of Omnicare's home infusion business.

3 Sep 2010

Emerald BioStructures, SomaLogic announce strategic collaboration for SOMAmers

Emerald BioStructures, a leading provider of integrated structural biology services, and SomaLogic, Inc., a diagnostics and biomarker discovery company, today announced that they have entered into a strategic collaboration for the structure-based design of chemically modified DNA aptamers and small molecule therapeutics, based on crystal structures of important protein targets bound to high affinity SOMAmers.

3 Sep 2010

GOG to conduct Phase II trial on primary peritoneal cancer

Oncolytics Biotech Inc. announced today that the Gynecologic Oncology Group (GOG) intends to conduct a randomized Phase II trial of weekly paclitaxel versus weekly paclitaxel with REOLYSIN(R) in patients with persistent or recurrent, ovarian, fallopian tube or primary peritoneal cancer (GOG186H).

3 Sep 2010

Biopharmaceutical firms take steps to create greener working environments

Biopharmaceutical firms and other life science organizations are taking definitive steps toward creating greener working environments and developing more sustainable operations, reports Genetic Engineering & Biotechnology News (GEN).

3 Sep 2010

Cetero Research launches series of scientific seminars to help researchers on clinical trial design

Cetero Research, the leading early-stage contract research organization (CRO), is launching a series of scientific seminars, "An Accelerated Path to Proof-of-Concept in Drug Development," designed to help pharmaceutical and biotechnology researchers learn the latest innovations in Phase I and IIa clinical trial designs.

3 Sep 2010

Fibrosis with inflammation after one year predicts risk of long-term kidney transplant failure

Kidney transplants that show a combination of fibrosis (scarring) and inflammation after one year are at higher risk of long-term transplant failure, according to a study appearing in an upcoming issue of the Journal of the American Society of Nephrology (JASN).

3 Sep 2010

Californians recognized for contributing to plasma protein lifesaving therapies

This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.

3 Sep 2010

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Seattle Genetics, Inc. announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc. The milestone was triggered by Agensys' initiation of a phase I trial for AGS-16M8F, an ADC for the treatment of cancer utilizing Seattle Genetics' technology.

3 Sep 2010

Study demonstrates safety of cord blood stem cell transplantation protocol to treat neurological conditions

In a new peer-reviewed article published by the Journal of Translational Medicine, scientists from Beike Biotechnology,China's leading stem cell research and regenerative medicine company, and Medistem, Inc.,reported positive safety data in 114 patients who were treated by doctors at Nanshan Affiliated Hospital of Guangdong Medical College (Shenzhen Nanshan Hospital) in Shenzhen using Beike's proprietary cord blood stem cell transplantation protocol.

3 Sep 2010

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Celsion Corporation, a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer".

3 Sep 2010

Shanghai SynTheAll Pharmaceuticals receives ISO 14001 certification

WuXi PharmaTech, a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that its manufacturing subsidiary, Shanghai SynTheAll Pharmaceuticals Co. Ltd. (STA) passed the ISO 14001: 2004 inspection conducted by SGS Group on July 1 and received formal ISO 14001 certification on July 30.

3 Sep 2010

iBio and CMB enter development and marketing collaboration with GE Healthcare

iBio, Inc., its development collaborator, Fraunhofer USA Center for Molecular Biotechnology (CMB), and GE Healthcare, a unit of General Electric Company, today announced their entry into an agreement to jointly develop and globally market manufacturing solutions for biopharmaceuticals and vaccines based upon their respective proprietary technologies.

2 Sep 2010

International consortium publishes third-generation map of human genetic variation

An international consortium today published a third-generation map of human genetic variation, called the HapMap, which includes data from an additional seven global populations, increasing the total number to 11 populations. The improved resolution will help researchers interpret current genome studies aimed at finding common and rarer genetic variants associated with complex diseases.

2 Sep 2010

Sigma-Aldrich Corporation announces global release of engineered mammalian cell lines

Sigma Life Science, the innovative biological products and research services business of Sigma-Aldrich Corporation, today announced the global release of a pioneering range of engineered mammalian cell lines.

2 Sep 2010

Biotechnology News and Research

Complete Genomics, SAIC-Frederick collaborate to validate somatic mutations from pediatric cancer cases

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Bend Research expands hot-melt extrusion pharmaceutical manufacturing capabilities

Researchers reveal new details on bacterial cannibalism

Exelixis grants 25,200 shares to nine new employees

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Omnicare, Walgreen announce closing of transaction

Emerald BioStructures, SomaLogic announce strategic collaboration for SOMAmers

GOG to conduct Phase II trial on primary peritoneal cancer

Biopharmaceutical firms take steps to create greener working environments

Cetero Research launches series of scientific seminars to help researchers on clinical trial design

Fibrosis with inflammation after one year predicts risk of long-term kidney transplant failure

Californians recognized for contributing to plasma protein lifesaving therapies

Seattle Genetics achieves milestone on Agensys' initiation of AGS-16M8F ADC phase I trial for cancer

Study demonstrates safety of cord blood stem cell transplantation protocol to treat neurological conditions

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Shanghai SynTheAll Pharmaceuticals receives ISO 14001 certification

iBio and CMB enter development and marketing collaboration with GE Healthcare

International consortium publishes third-generation map of human genetic variation

Sigma-Aldrich Corporation announces global release of engineered mammalian cell lines

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News